Cerezyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for gaucher disease, success of enzyme replacement therapies, improved rare disease diagnostics, early adoption in specialty clinics, regulatory support for orphan drugs.

The growth in the forecast period can be attributed to increasing awareness of lysosomal storage disorders, expansion of reimbursement coverage, advancements in biologic manufacturing, growth of home care infusion models, sustained orphan drug incentives. Major trends in the forecast period include continued reliance on enzyme replacement therapies, growing diagnosis rates of rare genetic disorders, shift toward long term disease management solutions, expansion of home based infusion therapies, focus on treatment accessibility for rare diseases.

The rising investment in research and development is expected to drive the growth of the Cerezyme market in the coming years. Research and development (R&D) involves the systematic exploration, innovation, and creation of new products, services, or technologies to improve or advance existing solutions. Investment in R&D is increasing due to growing demand for innovation, technological progress, and the need to address complex global challenges across industries. R&D supports Cerezyme by fostering innovations in enzyme replacement therapies, enhancing treatment efficacy, improving patient outcomes, and expanding its use in addressing unmet needs in managing Gaucher disease. For example, in January 2025, the G-FINDER 2024 report indicated that global funding for hepatitis C research rose by USD 5 million (30%) to USD 21 million in 2023 compared with 2022. Therefore, the rising investment in research and development is driving the growth of the Cerezyme market.

Rising healthcare infrastructure is also expected to propel the growth of the Cerezyme market. Healthcare infrastructure refers to the physical facilities, resources, and systems required to deliver medical services and support the functioning of healthcare systems. Growth in healthcare infrastructure is driven by population expansion, aging demographics, increasing healthcare needs, technological advances, and greater investment from governments and the private sector. Improved infrastructure supports Cerezyme by providing the necessary resources and advanced clinical settings to administer enzyme replacement therapy effectively. For example, in April 2025, the American Medical Association (AMA), a US-based professional association, reported that U.S. health spending increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person, up from a 4.6% growth rate in 2022. Therefore, rising healthcare infrastructure is driving the growth of the Cerezyme market.

A key trend in the Cerezyme market is the expansion of manufacturing facilities to increase production capacity, improve efficiency, and meet growing global demand. Biologics manufacturing facilities are specialized plants that use advanced technologies to produce high-quality biologic drugs, such as enzymes and antibodies, ensuring scalable production and regulatory compliance. For instance, in November 2024, Sanofi SA, a France-based pharmaceutical company, opened a $586 million (€558 million) modular vaccine and biologics manufacturing facility in Singapore. Located in Tuas Biomedical Park, the facility is designed to produce next-generation vaccines and biologic therapeutics simultaneously, with the capability to manufacture up to four products in parallel using 34 interconnected standardized production modules that can be rapidly reconfigured to meet specific needs. This advanced design strengthens Sanofi’s capacity to respond to surges in biopharmaceutical demand, including during potential pandemics.

Major companies operating in the cerezyme market are Sanofi S.A.

North America was the largest region in the cerezyme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cerezyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cerezyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the cerezyme market by raising costs for biologic raw materials, sterile manufacturing components, and import dependent enzymes. Hospital and specialty clinic segments experience higher procurement costs. Regions reliant on international enzyme supply chains are more affected. At the same time, tariffs are promoting localized biologics production. This supports long-term treatment continuity and supply security.

The cerezyme market research report is one of a series of new reports that provides cerezyme market statistics, including cerezyme industry global market size, regional shares, competitors with a cerezyme market share, detailed cerezyme market segments, market trends and opportunities, and any further data you may need to thrive in the cerezyme industry. This cerezyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cerezyme is an enzyme replacement therapy developed to treat Gaucher disease, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It helps manage symptoms such as enlargement of the spleen and liver, anemia, low platelet counts, and bone complications by replacing the missing or deficient enzyme, reducing the buildup of fatty substances in affected organs and tissues.

The primary indications for Cerezyme include Gaucher’s disease (type 1), Gaucher’s disease (type 3), and other lysosomal storage disorders. Gaucher’s Disease Type 1 is the most common form, characterized by fatty substance accumulation in organs such as the liver, spleen, and bones, leading to organ enlargement, bone pain, and anemia. Cerezyme is distributed through direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is used by hospitals, clinics, ambulatory care centers, and home care providers.

The cerezyme market consists of sales of specialized infusion equipment, gene therapy products, supportive care medications and nutritional supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.